Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Claes R. Andersson"'
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-10 (2022)
Abstract Understanding the immunological effects of chemotherapy is of great importance, especially now that we have entered an era where ever-increasing pre-clinical and clinical efforts are put into combining chemotherapy and immunotherapy to comba
Externí odkaz:
https://doaj.org/article/6dcaee7294064a91aaf98e56ddd64e38
Autor:
Tove Selvin, Malin Berglund, Anders Åkerström, Marco Zia, Jakob Rudfeldt, Malin Jarvius, Rolf Larsson, Claes R Andersson, Mårten Fryknäs
Publikováno v:
SLAS Technology, Vol 29, Iss 6, Pp 100232- (2024)
To facilitate the translation of immunotherapies from bench to bedside, predictive preclinical models are essential. We developed the in vivo immuno-oncology Hollow Fiber Assay (HFA) to bridge the gap between simpler cell-based in vitro assays and mo
Externí odkaz:
https://doaj.org/article/d2e6640e28ad4e36aa4dfe94b2089f19
Autor:
Tove Selvin, Malin Berglund, Lena Lenhammar, Malin Jarvius, Peter Nygren, Mårten Fryknäs, Rolf Larsson, Claes R Andersson
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-10 (2023)
Abstract Background High-throughput screening (HTS) of small molecule drug libraries has greatly facilitated the discovery of new cancer drugs. However, most phenotypic screening platforms used in the field of oncology are based solely on cancer cell
Externí odkaz:
https://doaj.org/article/6a001318eb47461bbdbb33b4e9a1a25b
Publikováno v:
Anti-cancer drugs. 34(1)
Cancer patients often suffer from cancer symptoms, treatment complications and concomitant diseases and are, therefore, often treated with several drugs in addition to anticancer drugs. Whether such drugs, here denoted as 'concomitant drugs', have an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::164087c63b701646df5f9b6c869a86ed
https://pubmed.ncbi.nlm.nih.gov/36066384
https://pubmed.ncbi.nlm.nih.gov/36066384